MAOB and Parkinson disease: Recently, Wu et al. (2020) synthesized a series of procaine-imidazole derivatives with potent and selective MAO-B inhibitory activity, as well as in vivo anti-Parkinson effects using a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease.